Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-820836 in Treatment Resistant Major Depression
NCT01309945Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2011
- Primary completion
- Jan 2013
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of liafensine in major depressive disorder (MDD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Montgomery Asberg Depression Rating Scale at 20 weeks. Started Apr 2011; status: completed.
02
Drugs
liafensine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01309945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01309945.